

2024

英文論文

1. 2024 Rossari F, Tada T, Suda G, Shimose S, **Kudo M**, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Burgio V, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A, Rimini M: α -FAtE: a new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. **Int J Cancer** 154:1043-1056, 2024. (IF=6.400)
2. 2024 Camera S, Rimini M, Rossari F, Tada T, Suda G, Shimose S, **Kudo M**, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Salani F, Marseglia M, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Lonardi S, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Foti S, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A: Safety and efficacy of lenvatinib in very old patients with unresectable hepatocellular carcinoma. **Target Oncol** 19:29-39, 2024. (IF=5.400)
3. 2024 Okushin K, Tateishi R, Hirakawa S, Tachimori H, Uchino K, Nakagomi R, Yamada T, Nakatsuka T, Minami T, Sato M,

2024

英文論文

- Fujishiro M, Hasegawa K, Eguchi Y, Kanto T, Yoshiji H, Izumi N, **Kudo M**, Koike K: The Impact of COVID-19 on the Diagnosis and Treatment of HCC: Analysis of a Nationwide Registry for Advanced Liver Diseases (REAL). **Sci Rep** 14:282696, 2024. (IF=4.600)
4. 2024 Celsa C, Cabibbo G, Fulgenzi C, Scheiner B, d'Alessio A, Mangredi GF, Nishida N, Ang C, Marron U, Saeed A, Wietharn B, Pinter M, Cheon J, Huang YH, Lee PC, Phen S, Gampa A, Pillai A, Vivaldi C, Salani F, Masi G, Bettinger D, Thimme R, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, **Kudo M**, Rimassa L, Singal AG, El Tomb P, Ulahannan S, Parisi A, Chon HJ, Hsu WF, Piscaglia F, Verzoni E, Giusti R, Veccia A, Catino A, Aprile G, Guglielmini PF, De Napoli M, Ermacora P, Antonuzzo L, Schinzari G, Verderame F, Zustovich F, Ficorella C, Morelli MF, Battelli N, Negrini G, Grossi F, Bordonaro R, Sabbatini R, Banzi M, Migliorino MR, Laera L, Russo A, De Giorgi U, Cavanna L, Soraru M, Montesarchio V, Bordi P, Brunetti L, Pinto C, Bersanelli M, Camma C, Cortellini A, Pinato DJ: Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours. **J Hepatol** 80:431-442, 2024. (IF=25.700)
5. 2024 Takenaka M, Lee TH, **Kudo M**: Recent advances in metallic stents used in the stent-in-stent method for hilar malignant biliary obstruction. **Dig Endosc** 36:370-372, 2024. (IF=5.300)
6. 2024 Otuska Y, Minaga K, **Kudo M**, Watanabe T: Role of leucine-rich repeat kinase 2 in severe acute pancreatitis. **Front Immunol** 15:1364839, 2024. (IF=7.300)
7. 2024 Hara A, Minaga K, Otsuka Y, Tanaka H, Takenaka M, **Kudo M**: Emergency digital cholangioscopy-assisted electrohydraulic lithotripsy for basket impaction with an entrapped bile duct stone. **Endosc Int Open** 12:E271-E273, 2024. (IF=2.600)

2024

英文論文

8. 2024 Hagiwara S, Tanizaki J, Hayashi H, Komeda Y, Nishida N, Yoshida A, Yamamoto T, Matsubara T, **Kudo M**: Hemophagocytic lymphohistiocytosis induced by nivolumab/ipilimumab combination therapy: A case of lung adenocarcinoma that responded to early steroid pulse therapy. **Cancer Rep** 7:e1960, 2024. (IF=1.700)
9. 2024 **Kudo M***: Objective response to systemic therapy is a strong predictor of overall survival in patients with unresectable hepatocellular carcinoma. **Liver Cancer** 13:1-5, 2024. <https://doi.org/10.1159/000535516> (IF=13.800)
10. 2024 Aoki T, **Kudo M***, Ueshima K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Tsurusaki M, Nishida N: Incidence of hyper progressive disease in combination immunotherapy and anti-PD-1/PD-L1 monotherapy for unresectable hepatocellular carcinoma. **Liver Cancer** 13:56-69, 2024. <https://doi.org/10.1159/000531024> (IF=13.800)
11. 2024 **Kudo M***, Ueshima K, Saeki I, Ishikawa T, Inaba Y, Morimoto N, Aikata H, Tanabe N, Wada Y, Kondo Y, Tsuda M, Nakao K, Ito T, Hosaka T, Kawamura Y, Kuzuya T, Nojiri S, Ogawa C, Koga H, Hino K, Ikeda M, Moriguchi M, Hisai T, Yoshimura K, Furuse J, Arai Y: A Phase 2, prospective, multicenter, single-arm trial of transarterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable Intermediate-stage hepatocellular carcinoma: TACTICS-L trial. **Liver Cancer** 13:99-112, 2024. <https://doi.org/10.1159/000531377> (IF=13.800)
12. 2024 Trevisani F, Vitale A, **Kudo M**, Kulik L, Park JW, Pinato DJ, Cillo U: Merits and boundaries of the Barcelona Clinic Liver Cancer staging and treatment algorithm: learning from the past to improve the future with a novel proposal. **J Hepatol**, 2024 (Epub ahead of print). (IF=25.700)

2024

英文論文

13. 2024 Balcar L, Scheiner B, Fulgenzi CAM, D'Alessio A, Pomej K, Roig MB, Meyer EL, Cheon J, Nishida N, Lee PC, Wu LL, Ang C, Krall A, Saeed A, Stefanini B, Cammarota A, Pressiani T, Abugabal YI, Chamseddine S, Wietham B, Parisi A, Huang YH, Phen S, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, von Felden J, Schulze K, Silletta M, Trauner M, Samson A, Wege H, Piscaglia F, Galle PR, Stauber R, **Kudo M**, Singal AG, Itani A, Ulahannan SV, Parikh ND, Cortellini A, Kaseb A, Rimassa L, Chon HJ, Pinato DJ, Pinter M: Sex-related differences in efficacy and safety of immunotherapy in hepatocellular carcinoma: systematic review and meta-analysis and validation in routine clinical practice. **JHEP reports**, 2024 (Epub ahead of print). (IF=8.300)
14. 2024 Piscaglia F, Ikeda K, Cheng AL, **Kudo M**, Ikeda M, Breder V, Ryoo BY, Modi K, Ren M, Ramji Z, Sung MW: Association between treatment-emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in REFLECT study. **Cancer**, 2024 (Epub ahead of print). (IF=6.200)
15. 2024 Hagiwara S, Nakagawa K, Komeda Y, Nishida N, Yoshida A, Yamamoto T, Matsubara T, **Kudo M**: A case of an splenic artery aneurysm and focal nodular hyperplasia associated with an abdominal vascular abnormality of hereditary hemorrhagic telangiectasia. **Intern Med**, 2024 (Epub ahead of print). (IF=1.200)
16. 2024 Sangro B, Chan SL, Kelley RK, Lau G, **Kudo M**, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK, for the HIMALAYA investigators: Four-year overall survival update from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. **Ann Oncol**, 2024 (Epub ahead of print). (IF=50.500)

2024

英文論文

17. 2024 El-Khoueiry AB, Trojan J, Meyer T, Yau T, Melero I, **Kudo M**, Hsu C, Kim TY, Choo SP, Kang YK, Yeo W, Chopra A, Soleymani S, Yao J, Neely J, Tschaika M, Welling TH, Sangro B: Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040. **Ann Oncol**, 2024 (Epub ahead of print). (IF=50.500)
18. 2024 Llovet JM, Pinyol R, Yarchoan M, Singal AG, Marron TU, Schwartz M, Pikarsky E, **Kudo M**, Finn RS: Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. **Nat Rev Clin Oncol**, 2024 (Epub ahead of print). (IF=78.800)
19. 2024 Hagiwara S, Takase T, Oda I, Komeda Y, Nishida N, Yoshida A, Yamamoto T, Matsubara T, **Kudo M**: Hereditary hemorrhagic telangiectasia with hepatic arteriovenous shunt diagnosed due to liver damage. **Clin J Gastroenterol**, 2024 (Epub ahead of print). (IF=1.000)